I talked with Rob yesterday and he said they had conversations with some institutional investors who laugh at the trading going on. The PH3 301 study changes make it more likely IV P gets approved...the market is responding backwards to the news. So BCRX is confident about their future and Rob said expecting HHS update that will help clear things up shortly.
He also reminded me that RDEA data was not an indepth report on their gout drug. BCRX feels very good with BCX1812!
Trading to me is evidence of short greed and ego and they will try to push pps until they have been satisfied regardless of retail trader carnage.